Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer
- 533 Downloads
Concerns about the potential for genomic advances to increase health disparities have been raised. Thus, it is important to assess referral and uptake of genetic counseling (GC) and testing in minority populations at high risk for hereditary breast and ovarian cancer (HBOC). Black women diagnosed with invasive breast cancer ≤age 50 in 2009–2012 were recruited through the Florida State Cancer Registry 6–18 months following diagnosis and completed a baseline questionnaire. Summary statistics, Chi-square tests, and path modeling were conducted to examine which demographic and clinical variables were associated with referral and access to genetic services. Of the 440 participants, all met national criteria for GC, yet only 224 (51 %) were referred for or received GC and/or HBOC testing. Variables most strongly associated with healthcare provider referral for GC included having a college education (OR 2.1), diagnosis at or below age 45 (OR 2.0), and triple negative tumor receptor status (OR 1.7). The strongest association with receipt of GC and/or HBOC testing was healthcare provider referral (OR 7.9), followed by private health insurance at diagnosis (OR 2.8), and household income greater than $35,000 in the year prior to diagnosis (OR 2.0). Study findings suggest efforts are needed to improve genetic services access among a population-based sample of high-risk Black women. These results indicate that socioeconomic factors and physician referral patterns contribute to disparities in access to genetic services within this underserved minority population.
KeywordsBRCA testing Genetic counseling Hereditary breast cancer Cancer registry Disparities
This work was supported by grants through the Bankhead Coley Granting agency (IBG10-34199) and the American Cancer Society (RSG-11-268-01-CPPB). Support for Deborah Cragun’s time was provided by a NCI R25T training grant awarded to Moffitt Cancer Center (5R25CA147832-04). This work has been supported in part by the Biostatistics Core (5P30CA076292-16) and Survey Core at the Moffitt Cancer Center, a National Cancer Institute Comprehensive Cancer Center (P30-CA076292). Cancer data for this study (analysis) were provided by the Florida Department of Health, Florida Cancer Data System (FCDS). Cancer data are made available to aid public health surveillance and research to advance cancer control and prevention activities to better serve the population at risk for developing cancer and improve treatment for cancer patients. The contents of this study are solely the responsibility of the authors and do not necessarily reflect the official view of the Florida Department of Health, Florida Cancer Data System. We thank the following members of our Community Advisory Panel for their valuable input: Joyce Austin, Sue Friedman, Benita Hayes, Evora Pimento, Peggie Sherry, Cheryl Clinton, Gwendolyn Dawson, Gloria Wood, Linda Paige, Deneen Wyman, Khaliah Fleming, and Valerie Poindexter.
Conflict of interest
The authors report no conflicts of interest.
- 1.Society AC (2014) Cancer facts & figures 2013 & 2014. American Cancer Society, Inc. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf. Accessed 10 Feb 2014
- 2.Centers for Disease Control and Prevention (2013) Breast cancer statistics. http://www.cdc.gov/cancer/breast/statistics/. Accessed 10 Jan 2014
- 7.Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822. doi: 10.1093/jnci/djt095 CrossRefPubMedGoogle Scholar
- 8.Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130. doi: 10.1086/375033 CrossRefPubMedCentralPubMedGoogle Scholar
- 9.Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384–1392. doi: 10.1038/bjc.2011.120 CrossRefPubMedCentralPubMedGoogle Scholar
- 13.Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, McKinnon WC, Petrucelli NM, Bennett RL, Trepanier AM (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161. doi: 10.1007/s10897-011-9462-x CrossRefPubMedGoogle Scholar
- 14.National Comprehensive Cancer Network (2014) Genetic/familial high-risk assessment: breast and ovarian. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. Accessed 10 July 2014
- 16.Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, Neuss MN, Hughes KS (2014) Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American society of clinical oncology quality oncology practice initiative. J Clin Oncol 32(8):824–829. doi: 10.1200/jco.2013.51.4661 CrossRefPubMedGoogle Scholar
- 17.Levy DE, Byfield SD, Comstock CB, Garber JE, Syngal S, Crown WH, Shields AE (2011) Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med 13(4):349–355. doi: 10.1097/GIM.0b013e3182091ba4 CrossRefPubMedCentralPubMedGoogle Scholar
- 23.Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G (2012) Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol 2012:298745. doi: 10.1155/2012/298745 CrossRefPubMedCentralPubMedGoogle Scholar
- 24.McCarthy AM, Bristol M, Fredricks T, Wilkins L, Roelfsema I, Liao K, Shea JA, Groeneveld P, Domchek SM, Armstrong K (2013) Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. Cancer. doi: 10.1002/cncr.28268 PubMedCentralGoogle Scholar
- 34.Bellcross CA, Leadbetter S, Alford SH, Peipins LA (2013) Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomark Prev 22(4):728–735. doi: 10.1158/1055-9965.EPI-12-1280 CrossRefGoogle Scholar
- 35.Thompson HS, Sussner K, Schwartz MD, Edwards T, Forman A, Jandorf L, Brown K, Bovbjerg DH, Valdimarsdottir HB (2012) Receipt of genetic counseling recommendations among black women at high risk for BRCA mutations. Genet Test Mol Biomark 16(11):1257–1262. doi: 10.1089/gtmb.2012.0114 CrossRefGoogle Scholar